

10/535523

JC14 Rec'd PCT/PTO 17 MAY 2005

Express Mail No. EV514612823US

Date of Deposit: May 17, 2005  
PATENT

WDN/SLR:dm 05/16/05 6395-66741-06 384187 1-009-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Thomas W. Hodge, Natalie J.  
Morey, Michael W. Shaw, Donald Rubin, and  
Anthony Sanchez

**Application No.** Currently unknown

**Filed:** Herewith

**Confirmation No.** Currently unknown

**For:** CELL LINES AND HOST NUCLEIC ACID  
SEQUENCES RELATED TO  
INFECTIOUS DISEASE

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 6395-66741-06

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(1)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS,

10/535523

JC14 Re PCT/PTO 17 MAY 2005

Express Mail No. EV514612823US

Date of Deposit: May 17, 2005

PATENT


WDN/SLR:dm 05/16/05 6395-66741-06 384187 I-009-02

please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	6395-66741-06
Application Number	Currently unknown <b>10/535523</b>
Filing Date	May 17, 2005
First Named Inventor	Hodge
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

## **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,928,881	7/27/1999	Barnette et al.
		6,080,576	6/27/2000	Zambrowicz et al.
		6,136,566	10/24/2000	Sands et al.
		6,139,833	10/31/2000	Burgess et al.
		6,207,371	3/27/2001	Zambrowicz et al.
		6,218,123	4/17/2001	Nehls et al.
		6,436,707	8/20/2002	Zambrowicz et al.
		6,448,000	9/10/2002	Rubin et al.

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 97/45543 A2	04.12.1997	The Government of the USA, as represented by the Secretary of the Dept. of Health and Human Services, National Institutes of Health
		WIPO	WO 01/83754 A2	08.11.2001	Immusol, Incorporated
		WIPO	WO 02/44321 A2	06.06.2002	Max-Planck-Gesellschaft Zur Förderung der Wissenschaften E.V.

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	6395-66741-06
Application Number	107535523
Filing Date	May 17, 2005
First Named Inventor	Hodge
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Froeyen et al., "RNA as a Target for Drug Design, the Example of Tat-TAR Interaction," <i>Curr. Top. Med. Chem.</i> 2:1123-1145 (2002).
		Gitlin et al., "Short Interfering RNA Confers Intracellular Antiviral Immunity in Human Cells," <i>Nature</i> 418:430-434 (2002).
		Gulakowski et al., "A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening," <i>J. Virol. Methods</i> 33:87-100 (1991).
		Hata et al., "A Simple Purification And Fluorescent Assay Method Of The Poliovirus 3C Protease Searching For Specific Inhibitors," <i>J. Virol. Methods</i> 84:117-126 (2000).
		Kashani-Sabet, "Ribozyme Therapeutics," <i>JID Symposium Proceedings</i> 7:76-78 (2002).
		Manetta et al., "Design and Implementation of a Particle Concentration Fluorescence Method for the Detection of HIV-1 Protease Inhibitors," <i>Anal. Biochem.</i> 202(1):10-15 (1992).
		Marschall et al., "Inhibition of Gene Expression with Ribozymes," <i>Cell Mol. Neurobiol.</i> 14:523-538 (1994).
		Scherr et al., "Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells," <i>Curr. Med. Chem.</i> 10:245-256 (2003).
		Singh et al., "The Complestatins as HIV-1 Integrase Inhibitors. Efficient Isolation, Structure Elucidation, and Inhibitory Activities of Isocomplestatin, Chloropeptin I, New Complestatins A and B, and Acid-Hydrolysis Products of Chloropeptin I," <i>J. Natl. Prod.</i> 64:874-882 (2001).
		Ueda et al., "An In Vitro System for Screening Anti-Hepatitis B. Virus Drugs," <i>Virology</i> 169:213-216 (1989).

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	